The Alliance for Aging Research sent a letter to the Centers for Medicare & Medicaid Services asking the deputy administrator to consider giving priority consideration to medicines with a longer expected price applicability as they select the next round of drugs for the Medicare Drug Price Negotiation Program, so as not to impede the development of cost-saving biosimilar alternatives.